

COURSE FACULTY, IAS–USA STAFF, AND BOARD OF DIRECTORS

FINANCIAL RELATIONSHIPS WITH COMMERCIAL ENTITIES

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, IAS–USA Board members, Viral Hepatitis Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the previous 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity. The **ACCME defines a commercial interest** as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The **ACCME** does not consider providers of clinical service directly to patients to be **commercial interests** – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” Below are the financial interests that faculty members of this course have had within the past 12 months as of the date listed. View the [Faculty Financial Disclosure Policy](#).

2020 IAS-USA GUIDELINES VIRTUAL COURSE – OCTOBER 29, 2020

Course Panelists	
<p>Constance A. Benson, MD, MPH Professor of Medicine ID Training Program Director Director, Antiviral Research Center (AVRC) PI/Director, HIV/AIDS Clinical Trials Unit University of California San Diego San Diego, California</p>	<p>Dr Benson has served on advisory and data safety monitoring boards for GlaxoSmithKline/ViiV Healthcare, received research grants awarded to her institution from Gilead Sciences, Inc., and serves as a consultant to NDA Partners, LLC. Her spouse has served as a consultant to CytoDyn, AbbVie and Sempra Energy; owns stock options in Antiva Biosciences and CytoDyn; has served on the board for Gilead Sciences, Inc., with payment remitted to his institution; and has served on data and safety monitoring boards for Gilead Sciences, Inc., and VIR. (Updated 07/27/20)</p>
<p>Susan P. Buchbinder Director, Bridge HIV San Francisco Department of Public Health Clinical Professor of Medicine and Epidemiology University of California San Francisco San Francisco, California</p>	<p>Dr Buchbinder has participated in research trials that received provision of medicines from Gilead Sciences, Inc. (Updated 06/20/20)</p>
<p>Carlos del Rio, MD Hubert Professor and Chair Department of Global Health Professor of Medicine Emory University School of Medicine Rollins School of Public Health Atlanta, Georgia</p>	<p>Dr del Rio has no relevant financial affiliations to disclose. (Updated 06/20/20)</p>
<p>Rajesh T. Gandhi, MD Professor of Medicine Harvard Medical School Boston, Massachusetts</p>	<p>Dr Gandhi has served as a consultant or advisor to Merck & Co, Inc. (Updated 06/28/20)</p>
<p>Jennifer F. Hoy, MBBS Professor of Medicine The Alfred Hospital Monash University Melbourne, Australia</p>	<p>Dr Hoy has served as an advisor for payment to her institution for Merck, Sharp & Dohme Australia, ViiV Healthcare, and Gilead Sciences, Inc. (Updated 06/20/20)</p>
<p>Raphael J. Landovitz, MD Associate Professor of Medicine Associate Director University of California Los Angeles Center for Clinical AIDS Research and Education University of California Los Angeles Los Angeles, California</p>	<p>Dr Landovitz has served as a consultant to Gilead Sciences, Inc, Merck & Co, Inc, and Roche. (Updated 10/01/20)</p>
<p>Jean-Michel Molina, MD, PhD Professor of Infectious Diseases University of Paris Diderot Paris, France</p>	<p>Dr Molina has received grant support paid to his institution from Gilead Sciences, Inc, and served as a consultant to Merck & Co, Inc, Gilead Sciences, Inc, ViiV Healthcare, Janssen Therapeutics, and Sanofi. (Updated 10/03/20)</p>

<p>Michael Saag, MD (Panel Chair) Professor of Medicine Jim Straley Chair in AIDS Research Director, Center for AIDS Research Associate Dean for Global Health, School of Medicine University of Alabama at Birmingham Birmingham, Alabama</p>	<p>Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc, and ViiV Healthcare. (Updated 06/20/20)</p>
<p>Paul E. Sax, MD Professor of Medicine Harvard Medical School Clinical Director, Division of Infectious Diseases Brigham and Women's Hospital Boston, Massachusetts</p>	<p>Dr Sax has served as a consultant or advisor to GlaxoSmithKline/ViiV, Janssen Therapeutics, Merck & Co, Inc, and Gilead Sciences, Inc. He has received grant support awarded to his institution from Gilead Sciences, Inc, and GlaxoSmithKline/ViiV. (Updated 06/20/20)</p>
<p>Davey M. Smith, MD Professor and Vice Chair of Faculty Department of Medicine Chief, Division of Infectious Diseases University of California San Diego Veterans Affairs San Diego Healthcare System La Jolla, California</p>	<p>Dr Smith has served as a consultant to Gilead Sciences, Inc, Merck & Co, Inc, Arena Pharmaceuticals, Bayer Inc, and the AIDS Healthcare Foundation, and received grant support awarded to his institution from ViiV Healthcare. (Updated 06/20/20)</p>
<p>Melanie A. Thompson, MD Principal Investigator AIDS Research Consortium of Atlanta Atlanta, Georgia</p>	<p>Dr Thompson's institution has received grants for research from CytoDyn, Inc, Cepheid, Inc, Kowa Pharmaceuticals America, Inc, Frontier Biotechnologies, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, and ViiV Healthcare. (Updated 08/6/20)</p>
<p>Paul A. Volberding, MD Professor of Medicine Co-Director, Center for AIDS Research Director, AIDS Research Institute University of California San Francisco San Francisco, California</p>	<p>Dr Volberding has served on data and safety monitoring boards for Merck & Co, Inc. (Updated 06/20/20)</p>

IAS–USA CME Planner and Reviewer

<p>Carlos del Rio, MD*</p>	<p>Dr del Rio has no relevant financial affiliations to disclose. (Updated 06/20/20)</p>
<p>Donna M. Jacobsen Executive Director/President IAS–USA</p>	<p>Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 10/21/20)</p>

IAS–USA Board of Directors

The nonstaff members of the IAS–USA Board of Directors are not compensated for their roles in governing and overseeing the IAS–USA. Please see <https://iasusa.org/about/ias-usa-board-of-directors/> for information about board members and a link to up-to-date financial disclosure information.